In a report released today, Jeffrey La Rosa from Leerink Partners maintained a Buy rating on Pyxis Oncology, with a price target of $7.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jeffrey La Rosa has given his Buy rating due to a combination of factors that highlight the potential of Pyxis Oncology’s lead candidate, micvotabart pelidotin (micvo). The promising prospects of micvo, an innovative antibody drug conjugate targeting EDB-FN, are expected to be a significant catalyst in the second half of 2025, particularly in treating squamous cell carcinoma of the head and neck (SCCHN). La Rosa sees a favorable risk-reward scenario with potential gains of up to 150% and limited downside, driven by the low market expectations and the current undervaluation of Pyxis’s stock.
Additionally, Pyxis’s financial position is solid, with a cash reserve of $90.4 million expected to support operations into the second half of 2026. The company’s recent milestone payment from its subsidiary’s licensing agreement and potential future royalties from sales in China further strengthen its financial outlook. These factors, combined with upcoming data releases from ongoing clinical trials, underpin La Rosa’s optimistic view and Buy rating for Pyxis Oncology.